Newsletter | May 2, 2024

05.02.24 -- Pioneering Optimal Cell And Gene Therapy Performance

Optimizing Human iPSC Aggregate And Organoid Production For Bioprinting

Bioprinting for clinical-scale tissue and organ manufacturing necessitates processes capable of generating clinically relevant quantities of hiPSCs. This study aimed to identify the optimal cell culture conditions to yield high cell density and maintain high cell viability with consistent aggregate morphology and pluripotency marker expression.

Enhancing An Upstream AAV8 Process For Better Downstream Performance

While several rAAV-mediated therapies have received approval, and many more are undergoing clinical trials, establishing an efficient rAAV process platform remains a challenge. Here, we present an example of a gene therapy bioprocess in which an AAV8 upstream process was optimized to enhance downstream process performance.

Robust Development Of Downstream Process Technologies For AAV

Producing adeno-associated viral vectors remains a challenge for manufacturers due to the complexity of developing platform production processes. The focus of this study was to optimize the three primary downstream processing steps for AAV particle purification utilizing a design of experiments (DoE) methodology and screening devices.

Optimizing Perfusion Parameters For Intensified Production Of CAR-T Cells

Achieving therapeutic doses in CAR-T cell therapies represents the longest phase of manufacturing. Watch to explore a variety of scalable expansion processes designed to help meet growing demand.

Innovative Preservation Solutions For Cell Therapy

From manufacturing to patient delivery, the low efficiency and poor biocompatibility of conventional preservatives are barriers to successful cell preservation. Learn about advanced solutions designed to help improve the stability and post-thaw viability of your cell therapy products.